Celcuity LLC
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Celcuity LLC.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 45.20 $ to 145.00 $ · Last price: 84.90 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Celcuity LLC CELC | 4.2 | – | -7.8 | – | 0.0 | – | 55.5 |
| Vertex Pharmaceuticals Inc VRTX | 130.6 | 31.3 | 24.5 | 55.0 | 38.1 | 9.6 | 33.4 |
| Regeneron Pharmaceuticals Inc REGN | 82.0 | 19.9 | 13.1 | 44.5 | 20.7 | 1.0 | 35.5 |
| Moderna Inc MRNA | 62.7 | – | 4.6 | -66.0 | -131.1 | -39.2 | 532.3 |
| argenx NV ARGX | 61.9 | 38.1 | 34.2 | 59.1 | 32.0 | 89.6 | 30.9 |
| Revolution Medicines Inc RVMD | 40.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 338.3 |
| BeiGene, Ltd. ONC | 40.0 | 63.1 | 34.1 | 88.9 | 19.1 | 40.2 | 6.4 |
| Alnylam Pharmaceuticals Inc ALNY | 32.6 | 61.8 | 28.4 | 79.7 | 23.0 | 65.2 | -48.1 |
| Royalty Pharma Plc RPRX | 32.5 | 31.8 | 19.6 | 95.8 | 100.3 | 5.1 | 68.6 |
| Median of companies shown | 40.9 | 34.9 | 19.6 | 57.0 | 20.7 | 7.3 | 35.5 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -3 | -3 | -0.49 | -3 | 6 | 6 |
| 2017 | 0 | -6 | -6 | -0.84 | -5 | 31 | 32 |
| 2018 | 0 | -8 | -7 | -0.74 | -6 | 25 | 26 |
| 2019 | 0 | -8 | -7 | -0.72 | -6 | 19 | 20 |
| 2020 | 0 | -10 | -9 | -0.92 | -7 | 12 | 13 |
| 2021 | 0 | -28 | -30 | -2.21 | -20 | 69 | 86 |
| 2022 | 0 | -39 | -40 | -2.62 | -36 | 134 | 176 |
| 2023 | 0 | -66 | -64 | -2.69 | -54 | 140 | 191 |
| 2024 | 0 | -113 | -112 | -2.83 | -83 | 116 | 245 |
| 2025 | 0 | -172 | -177 | -3.37 | -153 | 101 | 467 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.85 | – | 0 | -47.40 | -30,291.70 | -28 | -28 |
| 2025: Q1 | -0.86 | – | 0 | – | – | -36 | -36 |
| 2025: Q2 | -1.04 | – | 0 | – | – | -36 | -36 |
| 2025: Q3 | -0.98 | – | 0 | – | -28,444.20 | -45 | -45 |
| 2025: Q4 | -0.97 | – | 0 | -100.00 | – | -36 | -37 |
| 2026: Q1 | -0.97 | – | 0 | – | – | -55 | -55 |
| 2026: Q2 | -1.44 | -38.50 | – | – | – | -55 | -56 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Breakout & Setup
Momentum & Trend
- Gary Antonacci: Dual Momentum (Stock Adaptation)
- High ADR (≥5%)
- Power Trend
- RS Leader (≥90)
- Stan Weinstein: Stage 1
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -4.39 | -4.48 – -4.30 | 37 | -36.3% | 2 |
| 12/31/2027 | -0.08 | -0.73 – 0.57 | 370 | 98.2% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Celcuity ist ein klinisches Onkologie-Biotech (Gedatolisib) ohne KI-Umsatzquelle und ohne belegten operativen KI-Einsatz: In allen sechs geprüften Filings erscheint KI ausschließlich in generischen Risiko-Floskeln (KI-verstärkte Cyberangriffe, hypothetische Datenlecks durch generative KI bei Mitarbeitern oder Dienstleistern, allgemeine KI-Regulierungsunsicherheit) — die vier 10-Qs enthalten gar keinen KI-Bezug.
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-Q 2026-05-14 · 10-Q 2025-11-13 · 10-Q 2025-08-14 · 10-Q 2025-05-15 · 10-K 2026-03-26 · 10-K 2025-03-31
Rated on July 8, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 810.1%
- Share count grows by less than 3% a year 50.5%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 246 m net cash
- Operating cash flow covers the profits of the last three years 62 m
- Return on capital at 15% or higher, or up versus two years ago -40.8%
- Insiders hold at least 10% or are net buyers 10.0%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% 4,867.2%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 4,867.2%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -176.1%
- ROCE > 15% -40.8%
- Expected return > 10% 4,686.0%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Hahne Vicky | Chief Financial Officer | Other | 16,000 | 0.00 | – |
| Aug 14, 2026 | Laing Lance G. | Chief Science Officer | Other | 20,000 | 0.00 | – |
| Aug 14, 2026 | Sullivan Brian F. | Chief Executive Officer | Other | 80,000 | 0.00 | – |
| Jul 14, 2026 | Baker Bros. Advisors Lp | Former 10% owner | Sell | 2,838,632 | 102.50 | 290,959,780 |
| Jul 14, 2026 | Baker Bros. Advisors Lp | Former 10% owner | Sell | 261,368 | 102.50 | 26,790,220 |
The company
About the Company
Celcuity Inc., ein Biotechnologieunternehmen im klinischen Stadium, konzentriert sich auf die Entwicklung gezielter Therapien zur Behandlung verschiedener solider Tumore in den USA.
- Employees
- 155
- Headquarters
- Minneapolis, MN
- Address
- 2800 Campus Drive, 55441 Minneapolis, United States
- Phone
- (763) 392-0123
- Website
- celcuity.com
- IPO Date
- 09/20/2017
- ISIN
- US15102K1007
Management
| Name | Title | Birth Year |
|---|---|---|
| Brian F. Sullivan | Co-Founder, Chairman & CEO | 1962 |
| Lance G. Laing Ph.D. | Co-Founder, Chief Science Officer, VP, Secretary & Director | 1962 |
| Vicky Hahne CPA | Chief Financial Officer | 1966 |
| Jodi Sievers | Head of Investor Relations & Corporate Communications | – |
| Brent Eilefson | General Counsel | – |
| Sheri Smith | Acting Head of Clinical Operations | – |
| Igor Gorbatchevsky M.D. | Chief Medical Officer | – |
| Eldon C. Mayer III, M.B.A. | Chief Commercial Officer | 1961 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/26/2026 Celcuity Inc. (CELC): Regulation FD Disclosure; Other Events; Financial Statements and Exhibits SEC ↗
- 08/13/2026 Celcuity Inc. (CELC): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 07/14/2026 Celcuity Inc. (CELC): Regulation FD Disclosure; Other Events; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.